Dr. Carla Abdelnour, neurologist and member of the Fundació ACE clinical trials team, participates in the XVIII annual meeting of the AMN (Madrid Neurology Association) with a presentation entitled "Clinical aspects of dementia with Lewy bodies".
Dr. Abdelnour is one of the greatest experts in this pathology. Her involvement in the investigation of Lewy body dementia has resulted in a recent publication in the prestigious journal Neurology on Amyloid-β and tau biomarkers and clinical phenotype in dementia with Lewy bodies.
The working group that has prepared the study, formed among others, by the ELB-Consortium and Mayo Clinic, has offered results with important implications for the diagnosis, prognosis and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.
Lewy body dementia (LBD) is a difficult dementia to diagnose, especially in the early stages, since its symptoms coincide with those of other diseases such as Parkinson's or Alzheimer's.
It occurs especially from the age of 65 and, as far as we know, it does not have hereditary components. Its most frequent symptoms range from problems with balance and attention to visual or auditory hallucinations.
Due to the COVID-19 pandemic, this year the meeting is held online on October 22 and 23, 2020.
The objective of this XVIII edition is to be a meeting point between professionals, colleagues and friends to promote the collaborative spirit and jointly learn new aspects of the sector.